Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 16/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 11/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 10/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 10/20 | 0.44 |
| ▸ | EGFR | P00533 | 5/20 | 0.43 |
| ▸ | SRC | P12931 | 2/20 | 0.43 |
| ▸ | CSF1R | P07333 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4395699 | 0.97 | FGFR1 (0.44) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL4410416 | 0.94 | EGFR (0.43) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL4406798 | 0.93 | EGFR (0.44) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL4412501 | 0.91 | FGFR1 (0.42) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL4411349 | 0.90 | FGFR1 (0.48) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL4399033 | 0.90 | EGFR (0.43) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL4405793 | 0.90 | FGFR4 (0.51) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL4412250 | 0.88 | FGFR4 (0.43) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL4405363 | 0.88 | FGFR1 (0.49) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL4398515 | 0.88 | FGFR4 (0.47) | FGFR1FGFR4FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549651-B1 | PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS | WARNER LAMBERT CO (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7196090-B2 | Kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| WO-2006038112-A1 | USE OF KINASE INHIBITORS TO PROMOTE NEOCHONDROGENESIS | WARNER-LAMBERT COMPANY LLC (US) | 2006-04-13 | — | — | WO | disclosed |
| EP-1549651-A1 | KINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004011465-A1 | KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20040019210-A1 | Kinase inhibitors | CHIVIKAS CONNOLLY CLEO J (US) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019210-A1 | Kinase inhibitors | CDK2, CDK1, CDK4 | FGFR1 88/4885FGFR4 191/4885FGFR2 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.